RETURN HOME
Evaluation
Help us to design the most relevant educational programs for you. We really appreciate your feedback.
Country
(Required)
Select
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos Islands
Colombia
Comoros
Congo, Democratic Republic of the
Congo, Republic of the
Cook Islands
Costa Rica
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Côte d'Ivoire
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini (Swaziland)
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard and McDonald Islands
Holy See
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestine, State of
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Romania
Russia
Rwanda
Réunion
Saint Barthélemy
Saint Helena
Saint Kitts and Nevis
Saint Lucia
Saint Martin
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia
South Korea
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen Islands
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
US Minor Outlying Islands
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
Åland Islands
Profession
(Required)
Select
Medical oncologist
Surgeon
Pulmonologist
Other
Please specifiy profession
(Required)
How would you rate the overall quality of this treatment map?
(Required)
1=poor, 10=excellent
Select
10
9
8
7
6
5
4
3
2
1
How well did the learning activity fulfil the following objectives?
(Required)
Select the optimal treatment strategy for patients with
ALK
or
ROS1
mutation positive NSCLC
Extremely well
Very well
Quite well
Not well at all
How well did the learning activity fulfil the following objectives?
(Required)
Understand the clinical trial data supporting (currently) approved therapies, or emerging therapeutic options, guiding the optimal treatment approach
Extremely well
Very well
Quite well
Not well at all
How well did the learning activity fulfil the following objectives?
(Required)
Discuss how to identify, monitor and manage adverse events after ALK- or ROS1- tyrosine kinase inhibitors (TKI) therapy
Extremely well
Very well
Quite well
Not well at all
This activity:
(Required)
Was based on relevant and current/new evidence
Strongly agree
Agree
Not sure
Disagree
This activity:
(Required)
Has increased my knowledge of the subject
Strongly agree
Agree
Not sure
Disagree
This activity:
(Required)
Has increased my confidence in this subject
Strongly agree
Agree
Not sure
Disagree
This activity:
(Required)
Was focused on competencies relevant to my practice
Strongly agree
Agree
Not sure
Disagree
This activity:
(Required)
Will help me improve patient care within my clinical practice
Strongly agree
Agree
Not sure
Disagree
Will you make any measurable changes in practice by using this treatment map?
(Required)
Yes
Possibly, with further training or information
No, I am unable to at this time
Please select:
I will be able to confidently select the optimal treatment strategy for patients with
ALK
or
ROS1
mutation positive NSCLC
I will better understand clinical trial data supporting the approved therapies for this patient population
I will be able to explain how to identify, monitor and manage TKI treatment-related adverse events
I identify no specific changes but it has reinforced my current clinical practice
I will make a change not listed here
Please specify what other changes you would make.
What are the barriers that prevent you from making changes?
Did you feel there was any bias in the educational content?
No
Yes: Commercial (you felt there was undue prominence given to a specific product)
Yes: Professional (you felt there was inappropriate influence of a related organization)
Yes: Personal (the personal interests of the speaker caused bias)
Yes: other
Please specify what other bias(es) you felt were present.
Would you recommend this digital treatment map to a colleague?
Yes
No
Comments
This field is for validation purposes and should be left unchanged.
Educational grant
This independent content was supported by an educational grant from Pfizer.
Contact us
Springer Healthcare IME
IME@springer.com
The Campus, 4 Crinan Street London, N1 9XW, UK
© 2024
Springer Healthcare Ltd.
Part of the
Springer Nature Group.
Privacy policy
Terms & conditions
Manage cookies/Do not sell my data
Contact us
